102
Participants
Start Date
October 31, 2007
Primary Completion Date
January 31, 2011
Study Completion Date
February 29, 2012
Deferasirox (ICL670)
The recommended initial daily dose of Deferasirox is 20 mg/kg body weight.
Novartis Investigative Site, Istanbul
Novartis Investigative Site, Izmir
Novartis Investigative Site, Salamanca
Novartis Investigative Site, Valencia
Novartis Investigative Site, Singapore
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Nishinomiya
Novartis Investigative Site, Kahoku-gun
Novartis Investigative Site, Kanazawa
Novartis Investigative Site, Sayama
Novartis Investigative Site, Suita
Novartis Investigative Site, Shimotsuka-gun
Novartis Investigative Site, Simotsuke-city
Novartis Investigative Site, Bunkyo-ku
Novartis Investigative Site, Cyuo-ku
Novartis Investigative Site, Minato-ku
Novartis Investigative Site, Shinagawa-ku
Novartis Investigative Site, Shinjuku-ku
Novartis Investigative Site, Shinjuku-ku
Novartis Investigative Site, Hiroshima
Novartis Investigative Site, Kumamoto
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Nagasaki
Novartis Investigative Site, Toyama
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Adana
Novartis Investigative Site, Ankara
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY